References
- Kazandjian D, Blumenthal GM, Chen HY, et al. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. Oncologist 2014;19:e5-11
- Cohen MH, Williams GA, Sridhara R, et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003;8:303-6
- Cohen MH, Johnson JR, Chen YF, et al. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 2005;10:461-6
- Food and Drug Administration, Ministry of Public Health. Data of pharmaceutical products 2017. Available at: http://164.115.28.102/FDA_SEARCH_DRUG/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx [Last accessed 13 March 2017]
- Teerawattananon Y, Tritasavit N, Suchonwanich N, et al. The use of economic evaluation for guiding the pharmaceutical reimbursement list in Thailand. Z Evid Fortbild Qual Gesundhwesen 2014;108:397-404
- Bureau of Policy and Strategy. Public Health Statistics A.D.2014. Bangkok, Thailand: Ministry of Public Health, 2014
- National Cancer Institute. Cancer in Thailand Vol.VIII, 2010-2012. Bangkok, Thailand: Ministry of Public Health, 2015
- Chiang Mai Cancer Registry. Cancer Incidence and Mortality in Chiang Mai Maharaj Nakorn. Thailand: Chiang Mai Hospital, Faculty of Medicine, Chiang Mai University, 2009
- Tantraworasin A, Lertprasertsuke N, Kongkarnka S, et al. Retrospective study of ALK rearrangement and clinicopathological implications in completely resected non-small cell lung cancer patients in Northern Thailand: role of screening with D5F3 antibodies. Asian Pac J Cancer Prev 2014;15:3057-63
- Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94
- Sandler A, Gray R, Perry MC, et al. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
- Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 2005;11(2 Pt 1):690-6
- Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51
- Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97
- Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32
- Drug and Medical Supply Information Center. Ministry of Public Health, 2015. Available at: http://dmsic.moph.go.th [Last accessed 18 April 2016]
- Bureau of Trade and Economics Indices, Ministry of Commerce. CPI 2015. Available at: www.price.moc.go.th/price/cpi/index_new_e.asp [Last accessed 1 May 2016]
- Bank of Thailand. Foreign exchange rates 2015. Available at: https://www.bot.or.th/english/statistics/financialmarkets/exchangerate/_layouts/application/exchangerate/ExchangeRate.aspx [Last accessed 11 February 2016]
- Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices – budget impact analysis. Value Health 2007;10:336-47
- Thamlikitkul V. Health technology assessment in developing the National List of Essential Medicines in Thailand. J Med Assoc Thai 2014;97(Suppl5):S3
- Gainor JF, Varghese AM, Ou SH, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 2013;19:4273-81